Different Mitochondrial Defects Trigger Separate Longevity Pathways in C. elegans
Complex I and Complex IV defects each extend lifespan but through distinct molecular circuits, challenging the unified mitohormesis model.
Summary
Researchers at Mahidol University found that impairing Complex I (nuo-6) versus Complex IV (cco-1) of the mitochondrial electron transport chain extends C. elegans lifespan through fundamentally different signaling pathways. Complex I deficiency relies heavily on ATFS-1, the master regulator of the mitochondrial unfolded protein response (UPRmt), while Complex IV deficiency bypasses ATFS-1 and instead depends on the energy-sensing kinase AAK-2 (AMPK). Both defects activate UPRmt, yet the downstream genetic requirements diverge sharply. The diabetes drug metformin, a mild Complex I inhibitor, also produced complex-specific effects, suppressing longevity in nuo-6;aak-2 animals while trending toward extension in cco-1;aak-2 worms. These findings reveal that mitohormesis is not a single unified response but a collection of tailored, complex-specific retrograde signaling programs.
Detailed Summary
**Why this matters:** Mitohormesis — the paradoxical lifespan extension triggered by mild mitochondrial stress — is widely studied as a potential lever for healthy aging. A central assumption has been that different mitochondrial lesions converge on a shared protective mechanism. This study directly challenges that assumption, with implications for how we design and interpret pharmacological interventions targeting mitochondria in aging.
**What was studied:** Using C. elegans as a model organism, researchers systematically knocked down subunits of two different respiratory complexes — nuo-6 (Complex I) and cco-1 (Complex IV) — via RNA interference. They then crossed these knockdowns with silencing of atfs-1 (the UPRmt transcription factor) and aak-2 (the AMPK ortholog) to map which downstream pathways are required for longevity in each genetic background. The diabetes drug metformin (50 mM) was layered in as a pharmacological probe. Lifespan, UPRmt activation (via hsp-6p::GFP reporter), and AMPK phosphorylation (P-AAK-2 western blots) were measured.
**Key results:** Both nuo-6 and cco-1 knockdowns extended lifespan (median 19 vs. 24 days compared to 17 days for controls) and robustly induced the UPRmt. However, silencing atfs-1 largely abolished the longevity benefit of nuo-6 knockdown while having minimal effect on cco-1-mediated lifespan extension. Conversely, silencing aak-2 selectively blunted cco-1 longevity but left nuo-6 longevity largely intact. Metformin treatment of nuo-6;aak-2 double-knockdown animals markedly suppressed the residual longevity phenotype, whereas in cco-1;aak-2 animals metformin trended toward extension independent of AAK-2, suggesting an alternative, yet-unidentified effector pathway.
**Implications:** The study dismantles the concept of mitohormesis as a monolithic response and instead proposes that cells deploy molecularly tailored retrograde signaling networks depending on the specific site of ETC disruption. This has direct relevance for therapeutic strategies: drugs like metformin that target Complex I may have very different efficacy profiles — or even counterproductive effects — in individuals with pre-existing Complex I versus Complex IV dysfunction, such as those with mitochondrial disease or age-related respiratory decline.
**Caveats:** This is a preprint and has not yet undergone peer review. All experiments are conducted in C. elegans, an invertebrate model, and translation to mammals requires caution. The 50 mM metformin dose used in worms is pharmacologically supraphysiological relative to human therapeutic levels. The identity of the ATFS-1- and AAK-2-independent pathway mediating cco-1 longevity remains uncharacterized.
Key Findings
- Complex I (nuo-6) knockdown extends C. elegans lifespan primarily via the UPRmt regulator ATFS-1, not AMPK.
- Complex IV (cco-1) knockdown longevity requires AAK-2 (AMPK) and is largely independent of ATFS-1.
- Both ETC defects strongly activate UPRmt (hsp-6p::GFP), yet downstream genetic requirements diverge sharply.
- Metformin suppresses longevity in nuo-6;aak-2 worms but trends toward extension in cco-1;aak-2 animals.
- Mitohormesis is not a unified pathway — distinct ETC lesions engage complex-specific retrograde signaling networks.
Methodology
RNAi bacterial feeding was used in C. elegans N2 and SJ4100 reporter strains to knock down nuo-6, cco-1, atfs-1, and aak-2, singly and in combination. Lifespan was assessed in cohorts of ~100 synchronized animals; UPRmt was quantified via hsp-6p::GFP fluorescence and AMPK activity via phospho-Thr172 western blotting. Metformin (50 mM) was incorporated into NGM agar plates for pharmacological intervention experiments.
Study Limitations
This is an unreviewed preprint, and all findings are derived from C. elegans, limiting direct translation to humans or even mammals. The 50 mM metformin concentration is far above clinically relevant plasma levels in humans (~10–40 µM). The mechanistic identity of the ATFS-1-independent pathway driving cco-1 longevity remains unresolved and requires further investigation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: